The thesis

Roche operates in the pharmaceutical and diagnostics sectors with a gross margin of 73.32% and a P/E of 23.4x. The company's revenue growth is -1.8% YoY, indicating a slowdown. The conviction score is 0/100, classified as DORMANT, suggesting a lack of analyst conviction. The current macro context of escalating U.S. sanctions, particularly against institutions supporting Iran, creates a risk profile for Roche given its global operations.

Why now

The recent statements by U.S. Treasury Secretary Bessent about impending sanctions against financial institutions supporting Iran heighten the risk for global companies like Roche. The expectation of a 'wave of sanctions' indicates a potentially significant shift in the macro environment.

What to watch

The next quarter's revenue growth and any announcements regarding Roche's operations in countries under U.S. sanctions scrutiny will be critical indicators. The company's ability to navigate geopolitical risks and maintain its gross margin above 70% will be key to assessing its resilience.

Key risks

Roche's global operations, including in countries that may be subject to or affected by U.S. sanctions, pose a significant risk. The company's exposure to geopolitical tensions, particularly around Iran, could impact its business continuity and valuation. A major financial institution being sanctioned could have a ripple effect on the entire sector.

Theme exposure